David Berry to Participate in NewYorkBio and New York Stock Exchange Emerging Biotech Company Showcase

BOSTON, MA (Decem­ber 1, 2021) — Valo Health, LLC (“Valo”), the tech­nol­o­gy com­pa­ny using human-cen­tric data and arti­fi­cial intel­li­gence (AI) pow­ered com­pu­ta­tion to trans­form the drug dis­cov­ery and devel­op­ment process, announced today that its CEO and founder, David Berry, will par­tic­i­pate in this year’s NewYork­Bio and New York Stock Exchange’s Emerg­ing Biotech Com­pa­ny Show­case which brings togeth­er New York’s finan­cial com­mu­ni­ty and ground­break­ing biotech companies.

EVENT: NewYork­Bio & NYSE’s Emerg­ing Biotech Com­pa­ny Showcase 

WHAT: David Berry will join lead­ers from Cowen Inc and TMRW Life Sci­ence in a pan­el dis­cus­sion on the future of the biotech­nol­o­gy market. 

WHEN: Decem­ber 62021 

Full Event: 12:00 PM — 6:00 PM EST 

5:00 PM EST Pan­el Discus­sion: David Berry, Yaron Wer­ber, M.D., MBA, Cowen Inc., and Melanie Gold­ey, TMRW Life Sci­ences.

Reg­is­tra­tion for Vir­tu­al Tick­et: https://​newyork​bio​.glue​up​.com/…

About Valo Health, Inc.

Valo Health, LLC (“Valo”) is a tech­nol­o­gy com­pa­ny built to trans­form the drug dis­cov­ery and devel­op­ment process using human-cen­tric data and arti­fi­cial intel­li­gence (“AI”) com­pu­ta­tion. As a dig­i­tal­ly native com­pa­ny, Valo aims to full inte­grate human-cen­tric data across the entire drug devel­op­ment life­cy­cle into a sin­gle uni­fied archi­tec­ture, there­by accel­er­at­ing the dis­cov­ery and devel­op­ment of life-chang­ing drugs while simul­ta­ne­ous­ly reduc­ing the cost, time, and fail­ure rate. The company’s Opal Com­pu­ta­tion­al Plat­form™ con­sists of an inte­grat­ed set of capa­bil­i­ties designed to trans­form data into valu­able insights that may accel­er­ate dis­cov­er­ies and enable Valo to advance a robust pipeline of pro­grams across car­dio­vas­cu­lar meta­bol­ic renal, oncol­o­gy, and neu­rode­gen­er­a­tive dis­ease. Found­ed by Flag­ship Pio­neer­ing and head­quar­tered in Boston, MA, Valo also has offices in Lex­ing­ton, MA, San Fran­cis­co, CA, Prince­ton, NJ, and in Bran­ford, CT. To learn more, vis­it www​.val​o​health​.com.


Investors: Graeme Bell, Chief Finan­cial Officer



Media: Jen­nifer Han­ley, VP Cor­po­rate Communications